Abstract
Background
Levetiracetam has been widely used as a treatment option for different types of epilepsy in both adults and children. Because of its large between-subject variability, several population pharmacokinetic studies have been performed to identify its pharmacokinetic covariates, and thus facilitate individualised therapy.
Objective
The aim of this review was to provide a synopsis for population pharmacokinetic studies of levetiracetam and explore the identified influencing covariates.
Methods
We systematically searched the PubMed and Embase databases from inception to 30 June 2020. The information on study designs, target population, model characteristics, and identified covariates was summarised. Moreover, the pharmacokinetic profiles were compared among neonates, children, and adults.
Results
Fourteen studies were included, among which two involved neonates, four involved children, two involved both children and adults, and six involved adults only. The median value of apparent clearance for children (0.074 L/h/kg [range 0.038–0.079]) was higher than that for adults (0.054 L/h/kg [range 0.039–0.061]). Body weight was found to significantly influence the apparent clearance and volume of distribution, whereas renal function influenced the clearance. Likewise, coadministration with enzyme-inducing antiepileptic drugs (such as carbamazepine and phenytoin) increased the drug clearance by 9–22%, whereas coadministration with valproate acid decreased it by 18.8%.
Conclusion
Levetiracetam dose regimen is dependent on the body size and renal function of patients. Further studies are needed to evaluate levetiracetam pharmacokinetics in neonates and pregnant women.
Similar content being viewed by others
References
Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett. 2001;306(1–2):5–8.
Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002;43(1):9–18.
Weijenberg A, Bos JHJ, Schuiling-Veninga CCM, Brouwer OF, Callenbach PMC. Antiepileptic drug prescription in Dutch children from 2006–2014 using pharmacy-dispensing data. Epilepsy Res. 2018;146:21–7.
Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551–63.
Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43(11):707–24.
Strolin Benedetti M, Whomsley R, Nicolas J-M, Young C, Baltes E. Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur J Clin Pharmacol. 2003;59(8–9):621–30.
May TW, Rambeck B, Jürgens U. Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit. 2003;25(6):690–9.
Reisinger TL, Newman M, Loring DW, Pennell PB, Meador KJ. Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy. Epilepsy Behav. 2013;29(1):13–8.
Naik GS, Kodagali R, Mathew BS, Thomas M, Prabha R, Mathew V, et al. Therapeutic drug monitoring of Levetiracetam and lamotrigine: is there a need? Ther Drug Monit. 2015;37(4):437–44.
Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res. 1972;5(5):411–59.
Sasaki T, Tabuchi H, Higuchi S, Ieiri I. Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting. Pharmacogenomics. 2009;10(8):1257–66.
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.
Statistical approaches to establishing bioequivalence. US Department of Health and Human Services. Rockville: US FDA, US Center for Drug Evaluation and Research; 2001.
Kesselheim AS. The backlash against bioequivalence and the interchangeability of brand-name and generic drugs. CMAJ. 2011;183(12):1350–1.
Han N, Yun HY, Kim IW, Oh YJ, Kim YS, Oh JM. Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients. Eur J Clin Pharmacol. 2014;70(10):1211–9.
Snoeck E, Jacqmin P, Sargentini-Maier ML, Stockis A. Modeling and simulation of intravenous levetiracetam pharmacokinetic profiles in children to evaluate dose adaptation rules. Epilepsy Res. 2007;76(2–3):140–7.
Pigeolet E, Jacqmin P, Sargentini-Maier ML, Stockis A. Population pharmacokinetics of levetiracetam in Japanese and Western adults. Clin Pharmacokinet. 2007;46(6):503–12.
Chhun S, Jullien V, Rey E, Dulac O, Chiron C, Pons G. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy. Epilepsia. 2009;50(5):1150–7.
Hernández-Mitre MP, Medellín-Garibay SE, Rodríguez-Leyva I, Rodríguez-Pinal CJ, Zarazúa S, Jung-Cook HH, et al. Population pharmacokinetics and dosing recommendations of Levetiracetam in adult and elderly patients with epilepsy. J Pharm Sci. 2020;109(6):2070–8.
Ito S, Yano I, Hashi S, Tsuda M, Sugimoto M, Yonezawa A, et al. Population pharmacokinetic modeling of Levetiracetam in pediatric and adult patients with epilepsy by using routinely monitored data. Ther Drug Monit. 2016;38(3):371–8.
Jung YS, Lee SM, Park MS, Park K. Population pharmacokinetic model of levetiracetam in Korean neonates with seizures. Int J Clin Pharmacol Ther. 2018;56(5):217–23.
Karatza E, Markantonis SL, Savvidou A, Verentzioti A, Siatouni A, Alexoudi A, et al. Pharmacokinetic and pharmacodynamic modeling of levetiracetam: investigation of factors affecting the clinical outcome. Xenobiotica. 2020;50(9):1090–100.
Kim MJ, Yum MS, Yeh HR, Ko TS, Lim HS. Pharmacokinetic and pharmacodynamic evaluation of intravenous levetiracetam in children with epilepsy. J Clin Pharmacol. 2018;58(12):1586–96.
Lima-Rogel V, Lopez-Lopez EJ, Medellin-Garibay SE, Gomez-Ruiz LM, Romero-Mendez C, Milan-Segovia RC, et al. Population pharmacokinetics of levetiracetam in neonates with seizures. J Clin Pharm Ther. 2018;43(3):422–9.
Papa P, Oricchio F, Ginés M, Maldonado C, Tashjian A, Ibarra M, et al. Pharmacokinetics of subcutaneous levetiracetam in palliative care patients. J Palliat Med. 2020;10:1089.
Rhee SJ, Shin JW, Lee S, Moon J, Kim TJ, Jung KY, et al. Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy. Epilepsy Res. 2017;132:8–14.
Toublanc N, Lacroix BD, Yamamoto J. Development of an integrated population pharmacokinetic model for oral levetiracetam in populations of various ages and ethnicities. Drug Metab Pharmacokinet. 2014;29(1):61–8.
Toublanc N, Sargentini-Maier ML, Lacroix B, Jacqmin P, Stockis A. Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations. Clin Pharmacokinet. 2008;47(5):333–41.
Wang YH, Wang L, Lu W, Shang DW, Wei MJ, Wu Y. Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy. Acta Pharmacol Sin. 2012;33(6):845–51.
Italiano D, Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet. 2013;52(8):627–45.
Hämmerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin Pharmacokinet. 1998;35(1):49–64.
Dahlin MG, Wide K, Ohman I. Age and comedications influence levetiracetam pharmacokinetics in children. Pediatr Neurol. 2010;43(4):231–5.
Johannessen Landmark C, Baftiu A, Tysse I, Valsø B, Larsson PG, Rytter E, et al. Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication. Ther Drug Monit. 2012;34(4):440–5.
Colin PJ, Allegaert K, Thomson AH, Touw DJ, Dolton M, de Hoog M, et al. Vancomycin pharmacokinetics throughout life: results from a pooled population analysis and evaluation of current dosing recommendations. Clin Pharmacokinet. 2019;58(6):767–80.
Ahn JE, Birnbaum AK, Brundage RC. Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses. J Pharmacokinet Pharmacodyn. 2005;32(5–6):703–18.
Perucca E, Gidal BE, Baltès E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res. 2003;53(1–2):47–56.
Coupez R, Nicolas J-M, Browne TR. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia. 2003;44(2):171–8.
Johannessen SI, Battino D, Berry DJ, Bialer M, Krämer G, Tomson T, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit. 2003;25(3):347–63.
Snoeck E, Stockis A. Dose-response population analysis of levetiracetam add-on treatment in refractory epileptic patients with partial onset seizures. Epilepsy Res. 2007;73(3):284–91.
Silverstein FS, Ferriero DM. Off-label use of antiepileptic drugs for the treatment of neonatal seizures. Pediatr Neurol. 2008;39(2):77–9.
Agrawal A, Banergee A. A review on pharmacokinetics of levetiracetam in neonates. Curr Drug Metab. 2017;18(8):727–34.
Bansal R, Suri V, Chopra S, Aggarwal N, Sikka P, Saha SC, et al. Change in antiepileptic drug prescription patterns for pregnant women with epilepsy over the years: impact on pregnancy and fetal outcomes. Indian J Pharmacol. 2019;51(2):93–7.
Daugaard CA, Sun Y, Dreier JW, Christensen J. Use of antiepileptic drugs in women of fertile age. Dan Med J. 2019;66(8):A5563.
Koc G, Keskin Guler S, Karadas O, Yoldas T, Gokcil Z. Fetal safety of levetiracetam use during pregnancy. Acta Neurol Belg. 2018;118(3):503–8.
Voinescu PE, Pennell PB. Management of epilepsy during pregnancy. Expert Rev Neurother. 2015;15(10):1171–87.
Garrity LC, Turner M, Standridge SM. Increased levetiracetam clearance associated with a breakthrough seizure in a pregnant patient receiving once/day extended-release levetiracetam. Pharmacotherapy. 2014;34(7):128–32.
Thangaratinam S, Marlin N, Newton S, Weckesser A, Bagary M, Greenhill L, et al. AntiEpileptic drug monitoring in PREgnancy (EMPiRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies. Health Technol Assess. 2018;22(23):1–152.
Polepally AR, Pennell PB, Brundage RC, Stowe ZN, Newport DJ, Viguera AC, et al. Model-based lamotrigine clearance changes during pregnancy: clinical implication. Ann Clin Transl Neurol. 2014;1(2):99–106.
Acknowledgements
The authors would like to sincerely thank Dr. Silvia Romano Moreno from Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí, México; Dr. V. Lima-Rogel from the Neonatal Intensive Care Unit, Hospital Central ‘Dr. Ignacio Morones Prieto’, San Luis Potosí, México; Dr. Yun Seob Jung from the Department of Pharmacology, Yonsei University College of Medicine, Korea; and Dr. Brigitte Lacroix from UCB Pharma SA, Belgium, for providing details about the research and active discussions on the coding. The authors would also like to thank Hai-ni Wen, MPharm, and Yi-wei Yin, PharmD, from Shanghai Chest Hospital, and PhD candidate Xiao-qin Liu from Fudan University for their critical comments. Finally, the authors would like to thank Editage (http://www.editage.cn) for English-language editing.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
Professor Zheng Jiao is supported by the Key Innovative Team of Shanghai Top-Level University Capacity Building in Clinical Pharmacy and Regulatory Science at Shanghai Medical College, Fudan University (HJW-R-2019-66-19).
Conflict of interest
Zi-ran Li, Chen-yu Wang, Xiao Zhu, and Zheng Jiao declare they have no conflicts of interest.
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Availability of data and materials
Not applicable.
Code availability
Not applicable.
Author contributions
ZL, CW, and ZJ designed the review and planned the work that led to the manuscript. ZL and CW performed the literature search and data analysis. ZL, XZ, and ZJ drafted and revised the manuscript. All authors approved the final version of this manuscript.
Electronic supplementary material
Below is the link to the electronic supplementary material.
40262_2020_963_MOESM1_ESM.pdf
Fig. S1 Investigated and identified covariates for clearance of LEV. AST: aspartate aminotransferase; ALT: alanine aminotransferase; BMI: body mass index; BSA: body surface area; eGFR: the estimated glomerular filtration rate; Inducer: enzyme-inducing antiepileptic drugs (PDF 136 KB)
Rights and permissions
About this article
Cite this article
Li, Zr., Wang, Cy., Zhu, X. et al. Population Pharmacokinetics of Levetiracetam: A Systematic Review. Clin Pharmacokinet 60, 305–318 (2021). https://doi.org/10.1007/s40262-020-00963-2
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40262-020-00963-2